Show simple item record

Amantadine use in the French prospective NS-Park cohort

dc.rights.licenseopenen_US
dc.contributor.authorFABBRI, Margherita
dc.contributor.authorROUSSEAU, Vanessa
dc.contributor.authorCORVOL, Jean-Christophe
dc.contributor.authorSOMMET, Agnes
dc.contributor.authorTUBACH, Florence
dc.contributor.authorDE RYCKE, Yann
dc.contributor.authorBERTILLE, Nathalie
dc.contributor.authorSELVARASA, Yajiththa
dc.contributor.authorCARVALHO, Stephanie
dc.contributor.authorCHAIGNEAU, Veronique
dc.contributor.authorBREFEL-COURBON, Christine
dc.contributor.authorORY-MAGNE, Fabienne
dc.contributor.authorTESSIER, Samuel
dc.contributor.authorTIR, Melissa
dc.contributor.authorBEREAU, Matthieu
dc.contributor.authorMEISSNER, Wassilios G
dc.contributor.authorTHIRIEZ, Claire
dc.contributor.authorMARQUES, Ana
dc.contributor.authorREMY, Philippe
dc.contributor.authorSCHNEIDER, Vincent
dc.contributor.authorMORO, Elena
dc.contributor.authorDEFEBVRE, Luc
dc.contributor.authorHOUETO, Jean Luc
dc.contributor.authorPRANGE, Stephane
dc.contributor.authorEUSEBIO, Alexandre
dc.contributor.authorGENY, Christian
dc.contributor.authorFRISMAND, Solene
dc.contributor.authorDAMIER, Philippe
dc.contributor.authorREUTHER, Caroline Giordana
dc.contributor.authorCASTELNOVO, Giovanni
dc.contributor.authorBENATRU, Isabelle
dc.contributor.authorDE MAINDREVILLE, Anne Doe
dc.contributor.authorDRAPIER, Sophie
dc.contributor.authorMALTETE, David
dc.contributor.authorLAGHA-BOUKBIZA, Ouhaid
dc.contributor.authorRASCOL, Olivier
dc.contributor.authorFABBRI, Margherita
dc.contributor.authorROUSSEAU, Vanessa
dc.contributor.authorCORVOL, Jean-Christophe
dc.contributor.authorSOMMET, Agnes
dc.contributor.authorTUBACH, Florence
dc.contributor.authorDE RYCKE, Yann
dc.contributor.authorBERTILLE, Nathalie
dc.contributor.authorSELVARASA, Yajiththa
dc.contributor.authorCARVALHO, Stephanie
dc.contributor.authorCHAIGNEAU, Veronique
dc.contributor.authorBREFEL-COURBON, Christine
dc.contributor.authorORY-MAGNE, Fabienne
dc.contributor.authorTESSIER, Samuel
dc.contributor.authorTIR, Melissa
dc.contributor.authorBEREAU, Matthieu
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorMEISSNER, Wassilios
dc.contributor.authorTHIRIEZ, Claire
dc.contributor.authorMARQUES, Ana
dc.contributor.authorREMY, Philippe
dc.contributor.authorSCHNEIDER, Vincent
dc.contributor.authorMORO, Elena
dc.contributor.authorDEFEBVRE, Luc
dc.contributor.authorHOUETO, Jean Luc
dc.contributor.authorPRANGE, Stephane
dc.contributor.authorEUSEBIO, Alexandre
dc.contributor.authorGENY, Christian
dc.contributor.authorFRISMAND, Solene
dc.contributor.authorDAMIER, Philippe
dc.contributor.authorREUTHER, Caroline Giordana
dc.contributor.authorCASTELNOVO, Giovanni
dc.contributor.authorBENATRU, Isabelle
dc.contributor.authorDE MAINDREVILLE, Anne Doe
dc.contributor.authorDRAPIER, Sophie
dc.contributor.authorMALTETE, David
dc.contributor.authorLAGHA-BOUKBIZA, Ouhaid
dc.contributor.authorRASCOL, Olivier
dc.contributor.authorFABBRI, Margherita
dc.contributor.authorROUSSEAU, Vanessa
dc.contributor.authorCORVOL, Jean-Christophe
dc.contributor.authorSOMMET, Agnes
dc.contributor.authorTUBACH, Florence
dc.contributor.authorDE RYCKE, Yann
dc.contributor.authorBERTILLE, Nathalie
dc.contributor.authorSELVARASA, Yajiththa
dc.contributor.authorCARVALHO, Stephanie
dc.contributor.authorCHAIGNEAU, Veronique
dc.contributor.authorBREFEL-COURBON, Christine
dc.contributor.authorORY-MAGNE, Fabienne
dc.contributor.authorTESSIER, Samuel
dc.contributor.authorTIR, Melissa
dc.contributor.authorBEREAU, Matthieu
dc.contributor.authorMEISSNER, Wassilios G
dc.contributor.authorTHIRIEZ, Claire
dc.contributor.authorMARQUES, Ana
dc.contributor.authorREMY, Philippe
dc.contributor.authorSCHNEIDER, Vincent
dc.contributor.authorMORO, Elena
dc.contributor.authorDEFEBVRE, Luc
dc.contributor.authorHOUETO, Jean Luc
dc.contributor.authorPRANGE, Stephane
dc.contributor.authorEUSEBIO, Alexandre
dc.contributor.authorGENY, Christian
dc.contributor.authorFRISMAND, Solene
dc.contributor.authorDAMIER, Philippe
dc.contributor.authorREUTHER, Caroline Giordana
dc.contributor.authorCASTELNOVO, Giovanni
dc.contributor.authorBENATRU, Isabelle
dc.contributor.authorDE MAINDREVILLE, Anne Doe
dc.contributor.authorDRAPIER, Sophie
dc.contributor.authorMALTETE, David
dc.contributor.authorLAGHA-BOUKBIZA, Ouhaid
dc.contributor.authorRASCOL, Olivier
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAMIER FOUBERT, Alexandra
dc.date.accessioned2025-02-13T10:01:14Z
dc.date.available2025-02-13T10:01:14Z
dc.date.issued2024-07-01
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/204838
dc.description.abstractEnObjective: To assess amantadine use and associated factors in the patients with Parkinson’s disease (PD). Background: Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat “levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres. Methods: Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis). Results: Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12–18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users. Conclusions: About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs. © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2024.
dc.language.isoENen_US
dc.subject.enAmantadine
dc.subject.enMotor complications
dc.subject.enNS-Park
dc.subject.enParkinson’s disease
dc.title.enAmantadine use in the French prospective NS-Park cohort
dc.title.alternativeJ Neural Transm (Vienna)en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00702-024-02772-4en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38578434en_US
bordeaux.journalJournal of Neural Transmissionen_US
bordeaux.page799-811en_US
bordeaux.volume131en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCNRS
bordeaux.teamColl_ACTIVE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Neural%20Transmission&rft.date=2024-07-01&rft.volume=131&rft.issue=7&rft.spage=799-811&rft.epage=799-811&rft.au=FABBRI,%20Margherita&ROUSSEAU,%20Vanessa&CORVOL,%20Jean-Christophe&SOMMET,%20Agnes&TUBACH,%20Florence&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record